Abstract
In this report we show that Tyr568 and Tyr570 are phosphorylated in vivo in the Kit/stem cell factor receptor (Kit/SCFR) following ligand-stimulation. By mutation of Tyr568 and Tyr570 to phenylalanine residues and expression of the mutated receptors in porcine aortic endothelial (PAE) cells, we could demonstrate a loss of activation of members of the Src family of tyrosine kinases when Tyr568 was mutated, while mutation of Tyr570 only led to a minor decrease in activation of Src family members. Mutation of both tyrosine residues led to a complete loss of Src family kinase activation. Phosphorylation of the adapter protein Shc by growth factor receptors provides association sites for Grb2-Sos, thereby activating the Ras/MAP kinase pathway. A much lowered degree of Shc phosphorylation, Ras and Erk2 activation and c-fos induction was seen in the Y568F mutant, while in the Y570F mutant these responses were less affected. In contrast, the mitogenic response was only slightly reduced. In a mutant receptor with both Tyr568 and Tyr570 mutated to phenylalanine residues, no phosphorylation of Shc and no activation of Ras and Erk2 was seen in response to stem cell factor stimulation, very weak induction of c-fos was seen and the mitogenic response was severely depressed. These data show that Ras/MAP kinase activation and c-fos induction by Kit/SCFR are mediated by members of the Src family kinases. However, the mitogenic response is only to a minor extent dependent on Src kinase activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alai M, Mui AL, Cutler RL, Bustelo XR, Barbacid M and Krystal G. . 1992 J. Biol. Chem. 267: 18021–18025.
Barone MV and Courtneidge SA. . 1995 Nature 378: 509–512.
Besmer P. . 1991 Curr. Opin. Cell Biol. 3: 939–946.
Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B and Heldin C-H. . 1991 EMBO J. 10: 4121–4128.
Blume-Jensen P, Rönnstrand L, Gout I, Waterfield MD and Heldin C-H. . 1994 J. Biol. Chem. 269: 21793–21802.
Blume-Jensen P, Siegbahn A, Stabel S, Heldin C-H and Rönnstrand L. . 1993 EMBO J. 12: 4199–4209.
Blume-Jensen P, Wernstedt C, Heldin C-H and Rönnstrand L. . 1995 J. Biol. Chem. 270: 14192–14200.
Burgering BMT, Medema RH, Maassen JA, van de Wetering ML, van der Eb AJ, McCormick F and Bos JL. . 1991 EMBO J. 10: 1103–1109.
Cutler RL, Liu L, Damen JE and Krystal G. . 1993 J. Biol. Chem. 268: 21463–21465.
De Cesare D, Jacquot S, Hanauer A and Sassone-Corsi P. . 1998 Proc. Natl. Acad. Sci. USA 95: 12202–12207.
Fleischman RA. . 1993 Trends Genet. 9: 285–290.
Funasaka Y, Boulton T, Cobb M, Yarden Y, Fan B, Lyman SD, Williams DE, Anderson DM, Zakut R, Mishima Y. . 1992 Mol. Biol. Cell 3: 197–209.
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y and Kanakura Y. . 1993 J. Clin. Invest. 92: 1736–1744.
Gelderloos JA, Rosenkranz S, Bazenet C and Kazlauskas A. . 1998 J. Biol. Chem. 273: 5908–5915.
Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH and Shaw PE. . 1995 EMBO J. 14: 951–962.
Gille H, Sharrocks AD and Shaw PE. . 1992 Nature 358: 414–417.
Hansen K, Johnell M, Siegbahn A, Rorsman C, Engström U, Wernstedt C, Heldin C-H and Rönnstrand L. . 1996 EMBO J. 15: 5299–5313.
Herbst R, Lammers R, Schlessinger J and Ullrich A. . 1991 J,. Biol. Chem. 266: 19908–19916.
Herbst R, Munemitsu S and Ullrich A. . 1995 Oncogene 10: 369–379.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y. . 1998 Science 279: 577–580.
Hooshmand-Rad R, Yokote K, Heldin C-H and Claesson-Welsh L. . 1998 J. Cell Sci. 111: 607–614.
Kozlowski M, Larose L, Lee F, Le DM, Rottapel R and Siminovitch KA. . 1998 Mol. Cell. Biol. 18: 2089–2099.
Kypta RM, Goldberg Y, Ulug ET and Courtneidge SA. . 1990 Cell 62: 481–492.
Leevers SJ and Marshall CJ. . 1992 EMBO J. 11: 569–574.
Lev S, Givol D and Yarden Y. . 1991 EMBO J. 10: 647–654.
Linnekin D, DeBerry CS and Mou S. . 1997 J. Biol. Chem. 272: 27450–27455.
Miyazono K, Okabe T, Urabe A, Yamanaha M and Takaku F. . 1985 Biochem. Biophys. Res. Commun. 126: 83–88.
Mori S, Rönnstrand L, Yokote K, Engström Å, Courtneidge SA, Claesson-Welsh L and Heldin C-H. . 1993 EMBO J. 12: 2257–2264.
Pawson T. . 1995 Nature 373: 573–580.
Price DJ, Rivnay B, Fu Y, Jiang S, Avraham S and Avraham H. . 1997 J. Biol. Chem. 272: 5915–5920.
Reuter CWM, Catling AD and Weber MJ. . 1995 Methods in Enzymology 255: 245–256.
Roche S, Fumagalli S and Courtneidge SA. . 1995 Science 269: 1567–1569.
Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T and Pelicci PG. . 1994 Oncogene 9: 2827–2836.
Sasaoka T, Langlois WJ, Leitner JW, Draznin B and Olefsky JM. . 1994 J. Biol. Chem. 269: 32621–32625.
Simonson MS, Wang Y and Herman WH. . 1996 J. Biol. Chem. 271: 77–82.
Tauchi T, Feng GS, Marshall MS, Shen R, Mantel C, Pawson T and Broxmeyer HE. . 1994 J. Biol. Chem. 269: 25206–25211.
Timokhina I, Kissel H, Stella G and Besmer P. . 1998 EMBO J. 17: 6250–6262.
Truett MA, Blacher R, Burke RL, Caput D, Chu C, Dina D, Hartog K, Kuo CH, Masiarz FR, Merryweather JP, Najarian R, Pachl C, Potter SJ, Puma J, Quiroga M, Rall LB, Randolph A, Urdea MS, Valenzuela P, Dahl HH, Flavalaro J, Hansen J, Nordfang O and Ezban M. . 1985 DNA 4: 333–349.
van der Geer P, Wiley S, Gish GD and Pawson T. . 1996 Curr. Biol. 6: 1435–1444.
Witte ON. . 1990 Cell 63: 5–6.
Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U and Ullrich A. . 1987 EMBO J. 6: 3341–3351.
Yokote K, Mori S, Hansen K, McGlade J, Pawson T, Heldin C-H and Claesson-Welsh L. . 1994 J. Biol. Chem. 269: 15337–15343.
Acknowledgements
We thank Dr Tony Pawson for kindly providing the GST-SrcSH2 fusion protein. Christer Wernstedt and Ulla Engström are gratefully acknowledged for superior peptide sequencing and peptide synthesis, respectively. Recombinant human SCF was kindly provided by AMGEN.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lennartsson, J., Blume-Jensen, P., Hermanson, M. et al. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18, 5546–5553 (1999). https://doi.org/10.1038/sj.onc.1202929
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202929
Keywords
This article is cited by
-
Evolution of KIPPIS as a versatile platform for evaluating intracellularly functional peptide aptamers
Scientific Reports (2021)
-
A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth
Journal of Cancer Research and Clinical Oncology (2021)
-
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
Experimental Hematology & Oncology (2020)
-
XK-related protein 5 (XKR5) is a novel negative regulator of KIT/D816V-mediated transformation
Oncogenesis (2018)
-
SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation
Scientific Reports (2018)